Fulcrum Therapeutics Inc (FULC)
6.20
-0.08
(-1.27%)
USD |
NASDAQ |
Jun 28, 16:00
6.22
+0.02
(+0.32%)
After-Hours: 20:00
Fulcrum Therapeutics Research and Development Expense (Annual): 71.80M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 71.80M |
| December 31, 2022 | 76.78M |
| December 31, 2021 | 69.70M |
| December 31, 2020 | 59.04M |
| Date | Value |
|---|---|
| December 31, 2019 | 71.07M |
| December 31, 2018 | 25.18M |
| December 31, 2017 | 18.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
59.04M
Minimum
2020
76.78M
Maximum
2022
69.68M
Average
71.07M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Bristol-Myers Squibb Co | 9.299B |
| Moderna Inc | 4.845B |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |